FMP
Kodiak Sciences Inc.
KOD
NASDAQ
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
8.65 USD
-0.03 (-0.347%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Victor Perlroth M.D.
sector
Healthcare
industry
Biotechnology
website
https://kodiak.comexchange
NASDAQ
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry ...
CIK
0001468748
ISIN
US50015M1099
CUSIP
50015M109
Address
1200 Page Mill Road
Phone
650 281 0850
Country
US
Employee
111
IPO Date
Oct 4, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
KOD Financial Summary
CIK
0001468748
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
50015M109
ISIN
US50015M1099
Country
US
Price
8.65
Beta
2.25
Volume Avg.
364.51k
Market Cap
455.2M
Shares
-
52-Week
2.19-11.6
DCF
3.89
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.38
P/B
-
Website
https://kodiak.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest KOD News
It looks like there's no news available.
